tbuckley/cabot-search huggingface dataset:
Abstract 1889: Can the moonlighting glycolytic enzyme α-enolase be a therapeutic target in pancreatic cancer.
Authors: Michela Capello, Moitza Principe, Michelle Samuel Chattaragada, Chiara Riganti, Weidong Zhou, Sammy Ferri-Borgogno, Simona Rolla, Lance Liotta, Emanuel Petricoin, Paola Cappello, Francesco Novelli
Journal: Cancer Research (2013)

Abstract Aberrant metabolism together with invasion and metastasis are hallmarks of cancer. This is particularly true for pancreatic ductal adenocarcinoma (PDAC), characterized by rapid progression, invasiveness and resistance to treatments. We have previously described α-enolase (ENOA) as a PDAC-associated antigen. It is a moonlighting protein that works both as a key metabolic enzyme and as a membrane plasminogen receptor. In order to clarify its multifunctional role in pancreatic tumorigenesis we investigated the effect of ENOA knockdown in PDAC cells. Protein expression alterations following ENOA knockdown in the human PDAC cell line CFPAC-1 were revealed by LC-MS/MS analysis. On the basis of a spectra count label-free quantitation approach a large number of proteins mainly involved in cell adhesion, metabolism and proliferation were found to be differentially expressed in ENOA silenced cells compared to the control. After ENOA silencing, PDAC cells displayed a delay in proliferation and decreased survival and colony formation capabilities, even if the pyruvate production was not affected. The growth inhibition was partially due to an increased concentration of intracellular reactive oxygen species (ROS) mainly generated through the sorbitol and NADPH oxidase pathways. Moreover in ENOA silenced cells, the in vitro plasminogen-driven invasion was abolished and the number of lung tumor masses was significantly reduced in SCID-beige mice injected with ENOA silenced cells compared to mice injected with control cells. These effects are under further confirmation in other PDAC cell lines. All together, these findings propose ENOA as a promising target for developing new therapies in pancreatic cancer management. Citation Format: Michela Capello, Moitza Principe, Michelle Samuel Chattaragada, Chiara Riganti, Weidong Zhou, Sammy Ferri-Borgogno, Simona Rolla, Lance Liotta, Emanuel Petricoin, Paola Cappello, Francesco Novelli. Can the moonlighting glycolytic enzyme α-enolase be a therapeutic target in pancreatic cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1889. doi:10.1158/1538-7445.AM2013-1889
SP0109 Biomarkers: How to Find and Develop Novel and Biologically Relevant Candidates?
Authors: A. C. Bay-Jensen
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> The degree of inflammation in auto-immune diseases such as rheumatoid arthritis (RA) is often assessed in serum and used for diagnostic and prognostic purposes. The serum levels of acute inflammatory signaling molecules [C-reactive protein (CRP), serum amyloid A (SAA)] in conjunction with the important pro-inflammatory cytokines themselves may have limited utility due to several limitations: 1: These traditional biomarkers are associated with substantial variation due to biological not technical issues 2: The combined burden of cytokines rather than one single player may be responsible for the progression of disease 3: The cellular and tissue origins of cytokines that are detected systemically are difficult to determine as the cytokines lack tissue specificity 4: There is substantial redundancy in the signaling potential of cytokines. Despite these major limitations, the total burden of inflammatory signaling molecules and pro-inflammatory cytokines are important in assessing the degree of inflammation in conjunction with a diagnosis of disease. The total burden of signaling ultimately results in protease expression, tissue destruction and disease progression (figure). One of the pivotal events in the downstream inflammatory signaling is the generation of pathological enzymes, which results in the release of small but tissue-specific protein fragments into the serum that may be used as molecular biochemical markers. We discuss the potential of this new class of biochemical markers, which may be viewed as "end products of tissue destruction". These so-called protein fingerprints may also be considered end-products of the convergence cytokine signaling pathways, as they are the final end-result of tissue destruction. Identification and employment of protein fingerprint biomarkers may be more biological relevant biomarker for rheumatic disease in monitoring treatment efficacy and prediction of response to intervention. <h3>Image/graph</h3> <h3>Disclosure of Interest</h3> A. Bay-Jensen Employee of: Nordic Bioscience a privately owned company involved in development of novel biomarkers
SOLUBLE ST2 IS AFFECTED BY PULMONARY HYPERTENSION SEVERITY IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
Authors: Jigar Contractor, Roderick Deano, Jackie Szymonifka, Qing Zhou, Jonathan Beaudoin, James Januzzi, Jagmeet Singh, Quynh Truong
Journal: Journal of the American College of Cardiology (2016)
Abstract 3010: Evaluation of genome wide analysis platforms for chromatin immunoprecipitation
Authors: Lin Ma
Journal: Cancer Research (2011)

Abstract Chromatin states can influence transcription directly by altering the packaging of DNA to allow or prevent access to DNA-binding proteins, or they can modify the nucleosome surface to enhance or impede recruitment of effector protein complexes. Genome-wide mapping of protein-DNA interaction and epigenetic marks helps to better understand the transcriptional regulation. Prior to the development of next gen sequencing technologies, chip on chip or location analysis was the method of choice for exploring genome wide protein:DNA occupancy patterns. ChIP-seq is increasing in popularity due to the data density and lack of interrogation bias that this platform provides. While this application is becoming more popular, few studies have been performed which explore differences in binding site profiles obtained from both methods. Here we present data which compares the performance of ChIP antibodies by ChIP-chip as well as by ChIP-seq. For theses studies, chIP-chip using Agilent microarrays and ChIP-seq using the Illumina Genome Analyzer platform were performed. These studies may serve as a basis to allow the development of specifications for acceptable performance on these genome wide platforms to facilitate the comparison of data sets in shared databases and in published research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3010. doi:10.1158/1538-7445.AM2011-3010
Hyperuricemia in Primary and Renal Hypertension
Authors: Paul J. Cannon, William B. Stason, Felix E. Demartini, Sheldon C. Sommers, John H. Laragh
Journal: New England Journal of Medicine (1966)

AN increased incidence of hyperuricemia in patients with primary hypertension has been cited in several reports.1 2 3 The present investigation of the population of the Hypertension-Nephritis Clinic of the Presbyterian Hospital in New York City confirms this observation among patients with either primary or renal hypertension, treated and untreated. The data from a related series of studies suggest that the hyperuricemia in both types of hypertension results from diminished renal excretion of urate. Altered lactic acid metabolism in hypertensive disease may account in part for the altered renal transport of uric acid.4 The results also raise the possibility that elevations of . . .
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia
Authors: Alessio Imperiale, Thibault Bahougne, Bernard Goichot, Philippe Bachellier, David Taïeb, Izzie Jacques Namer
Journal: Clinical Nuclear Medicine (2014)

(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with insulinoma.
OP0044 The effects of multiple doses of sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass
Authors: D. Padhi, M. Allison, A.J. Kivitz, M.J. Gutierrez, B. Stouch, C. Wang, G. Jang
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> AMG 785 is a sclerostin antibody (Scl-Ab) that blocks sclerostin from inhibiting osteoblast maturation and function and has been shown to stimulate bone formation. <h3>Objectives</h3> Evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of multiple doses of Scl-Ab in healthy men and postmenopausal women with low bone mass. <h3>Methods</h3> This double-blind, placebo-controlled, randomized, ascending multiple dose study enrolled healthy men and postmenopausal women aged 45 to 80 years with a lumbar spine or total hip DXA T-score ≤–1.0 and ≥–2.5. Subjects were enrolled into 1 of 6 groups and were then randomized 3:1 to Scl-Ab or placebo. Women received 6 subcutaneous doses of 1 mg/kg or 2 mg/kg Scl-Ab once every 2 weeks (Q2W), or 3 doses of 2 mg/kg or 3 mg/kg Scl-Ab once every 4 weeks (Q4W). Men received 1 mg/kg Scl-Ab Q2W or 3 mg/kg Scl-Ab Q4W. All subjects were instructed to take daily supplements containing calcium and vitamin D. PK, PD, and safety were monitored for up to 24 weeks. <h3>Results</h3> Enrolled subjects (36 Scl-Ab, 12 placebo) had a mean age of 59 years and a mean lumbar spine DXA T-score of –1.20 (Scl-Ab) and –1.29 (placebo). Mean serum Scl-Ab exposures were similar in women and men and increased approximately dose-proportionally across the Q2W and Q4W dose ranges. During the treatment period, Scl-Ab caused maximum increases from baseline in PINP of 66% to 147% across cohorts and maximum decreases from baseline in sCTX of 15% to 50% across cohorts. Scl-Ab treatment significantly increased lumbar spine BMD from baseline, reaching a maximum of 7.2% at 18 weeks (Figure). Two subjects tested positive for neutralizing antibodies with no discernable effects on PK, PD, or safety. Adverse event rates were balanced between groups and no significant safety findings were observed. <h3>Conclusions</h3> Multiple doses of Scl-Ab significantly increased the bone formation marker PINP, decreased the bone resorption marker sCTX, increased lumbar spine BMD, and were well tolerated in healthy men and postmenopausal women with low bone mass. These data support the continued clinical investigation of sclerostin inhibition as a potential therapeutic strategy for conditions that would benefit from increased bone formation. <h3>Acknowledgement</h3> This study was sponsored by Amgen Inc. and UCB Pharma. <h3>Disclosure of Interest</h3> D. Padhi Shareholder of: Amgen Inc., Employee of: Amgen Inc., M. Allison: None Declared, A. Kivitz Speakers Bureau: Amgen Inc., M. Gutierrez: None Declared, B. Stouch Shareholder of: Amgen Inc., Employee of: Amgen Inc., C. Wang Shareholder of: Amgen Inc., Employee of: Amgen Inc., G. Jang Shareholder of: Amgen Inc., Employee of: Amgen Inc.
AB0715 The Frequency of Spondyloarthropathy in Inflammatory Bowel Diseases
Authors: O. Kucuksahin, A. Ateş, M. Törüner, N. Türkçapar, A. Şahin, M. Turgay, G. Kınıklı, H. Çetinkaya, N. Düzgün
Journal: Annals of the Rheumatic Diseases (2014)

The present work demonstrates quantitative autoradiography by using positron emission tomography tracers and storage phosphorimaging plates. The uptake and association of [<sup>11</sup>C]<i>N</i>-methyl-4-piperidylbenzilate was measured in rat brain tissue cryosections of various thicknesses. The signal increased with increasing section thickness, but only in 10-μm-thick sections did the binding reach the steady state during a 50-min observation time. This violation of the equilibrium condition, potentially combined with perfusion limitations, leads to erroneous increased binding-site density and decreased affinity in the 25- and 50-μm-thick sections. For better imaging of receptor distribution it is reasonable to use thicker sections. For quantitative analysis of receptor-binding parameters, the specific properties of ligands at different thicknesses of cryosections need to be considered. Evidence is provided that the nonselective muscarinic antagonist<i>N</i>-methyl-4-piperidylbenzilate binds preferentially to the M<sub>4</sub> subtype of muscarinic acetylcholine receptors.
Use of Single Voided Urine Samples to Estimate Quantitative Proteinuria
Authors: Jay M. Ginsberg, Bruce S. Chang, Richard A. Matarese, Serafino Garella
Journal: New England Journal of Medicine (1983)

Quantitation of urinary protein excretion is used extensively for diagnostic and prognostic purposes and to assess the effects of therapy. The method most commonly used to measure urinary protein relies on 24-hour urine collections, which are time consuming, cumbersome, and often inaccurate. We reasoned that the urinary protein/creatinine ratio in a single voided urine sample should correlate well with the quantity of protein in timed urine collections. In a study of 46 specimens we found an excellent correlation between the protein content of a 24-hour urine collection and the protein/creatinine ratio in a single urine sample. The best correlation was found when samples were collected after the first voided morning specimen and before bedtime. We conclude that the determination of the protein/creatinine ratio in single urine samples obtained during normal daylight activity, when properly interpreted by taking into consideration the effect of different rates of creatinine excretion, can replace the 24-hour urine collection in the clinical quantitation of proteinuria. In the presence of stable renal function, a protein/creatinine ratio of more than 3.5 (mg/mg) can be taken to represent "nephrotic-range" proteinuria, and a ratio of less than 0.2 is within normal limits.
Twitter at the 2014 and 2015 Annual Meetings of the American Academy of Ophthalmology
Authors: Steven M. Christiansen, Thomas A. Oetting, Natasha L. Herz, Janice C. Law, Christopher P. O'Brien, Purnima S. Patel, Roma Patel, Jeff H. Pettey, Diana R. Shiba, Grace Sun, Tamara Fountain
Journal: Ophthalmology (2016)
PMO-261 Is Crohn's disease in the UK being under treated? Data from the 3rd round UK IBD audit: Abstract PMO-261 Table 1
Authors: G Walker, I Arnott, C Probert
Journal: Gut (2012)

<h3>Introduction</h3> The British Society Gastroenterology (BSG) guidelines for Inflammatory Bowel Disease (IBD) advise escalating treatment to immunosuppressives (IS) in severe relapsing disease and cases requiring repeated corticosteroids (CS). Anti-TNF (aTNF) therapy is recommended as 2nd line therapy. We used data collected in the 3rd Round UK IBD Audit to see how newly diagnosed and established patients with IBD are treated following hospital admission. <h3>Methods</h3> Retrospective patient data from 198 UK sites were collected using an online form with up to 40 patients per site. Inclusion criteria were age &gt;17 years, admission date from September 2010 to August 2011 and a discharge diagnosis of IBD. Relevant ICD10 and OPCS codes were provided. Data items collected included established/new diagnosis of IBD and drug treatment on discharge from hospital following admission with active disease. Incomplete data were excluded. Statistical analysis used Fishers exact test. <h3>Results</h3> Approximately 15%–20% newly diagnosed IBD patients are discharged with IS and/or aTNF therapy (CD 19.4%, 67/345; UC 15.0%, 63/420, p=0.18). Treatment patterns for established and newly diagnosed IBD patients are broadly similar but established CD patients are more frequently discharged with IS and/or aTNF compared with established UC (CD 52.1%, 924/1773; UC 39.8%, 638/1602, p&lt;0.0001). 1/4 newly diagnosed CD patients are discharged on no treatment, significantly less than in UC (CD 26.4%, 91/345, UC 10.7%, 45/420, p&lt;0.0001). Patients with established CD are twice as likely to be discharged on IS combined with aTNF compared with established UC (CD 12.5%, 221/1773; UC 5.5%, 88/1602, p&lt;0.0001). <h3>Conclusion</h3> The treatment of new IBD in the UK is relatively aggressive with 15% of UC and 20% of CD patients discharged after their first admission with IS or aTNF therapy. This is in contrast to those with established IBD. Only 50% of established CD patients are on IS or aTNF. Effective control of inflammation may prevent long term complications and there may be room for improvement with these patients. <h3>Competing interests</h3> None declared.
Cancer Patient Groups Grow In Democratic Hungary
Authors: Lou Fintor
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Cancer Patient Groups Grow In Democratic Hungary Get access Lou Fintor Lou Fintor Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 2, 20 January 1993, Pages 86–88, https://doi.org/10.1093/jnci/85.2.86 Published: 20 January 1993
P76 Meta-analysis of published evidence supports use of King's College criteria over model for end stage liver disease in outcome prediction in acute liver failure
Authors: M. J. W. McPhail, N. Senvar, J. A. Wendon, W. Bernal
Journal: Gut (2011)

<h3>Introduction</h3> Outcome prediction is a cornerstone of the management of Acute Liver Failure (ALF) where Emergency Liver Transplantation (ELT) is indicated for predicted death. The King9s College Criteria (KCC) for paracetamol overdose (POD) and non-POD ALF are the benchmark prognostic scores but recent reports have suggested the Modified End Stage Liver Disease (MELD) score could replace KCC. <h3>Aim</h3> To meta-analyse and compare diagnostic performance for outcome prediction of KCC and MELD in ALF. <h3>Method</h3> A systematic database search was performed and retrieved articles graded according to a pre-agreed proforma of methodological quality. Collated data were meta-analysed for summary sensitivity, specificity, Diagnostic OR, DOR meta-regression and ROC curve analysis. Pre-specified subgroup analysis was performed on the basis of methodological quality, the severity of hepatic encephalopathy (HE) of reported patients, and exclusion of those who underwent ELT. <h3>Results</h3> 32 studies published between 1992 and 2009 with data on 3008 patients (2464 from KCC and 544 MELD) were available for production of 2×2 tables. Taking data where transplanted patients were excluded summary sensitivity for KCC was 63 (95% CI 60 to 66) %, specificity 91 (90 to 93) % and DOR 18 (8.9 to 37). Summary sensitivity for MELD was 82 (95% CI 77 to 86) %, specificity 65 (59to71) % and DOR 11 (5.3 to 23; RDOR 0.75 (0.18 to 3.13))). Despite different MELD cut-offs between studies no statistical evidence of threshold was found and the AUROC for MELD was 0.83 (SE 0.05) and 0.88 (0.03) for KCC. A lack of patient level data prevented statistical comparison between these areas. The DOR for KCC in POD ALF was 27 (9–83) and 13 (5–31) in non-POD ALF. Heterogeneity (using the I<sup>2</sup> statistic) in the DOR for MELD was 49% and 80% for KCC although this was not dependent on aetiology. The lower sensitivity for KCC could be overcome by dynamic application of the criteria. <h3>Conclusion</h3> MELD is not superior to KCC on the basis of quantitative analysis of published evidence. While both scores may give complementary sensitivity and specificity (particularly in cases where bilirubin may have more prognostic value) the DOR and AUROC superiority of KCC suggest they should remain the preferred method of outcome prediction and listing decision for ELT in ALF, particularly in cases of POD-ALF.
ESTUDIO DESCRIPTIVO SOBRE EL ACLARAMIENTO COMPLETO DE COLÉDOCOLITIASIS EN LA 1 ° SESIÓN DE CPRE SOBRE PAPILA NÄIVE
Authors: E Martos, MP Delgado, L Santos, F Sánchez, JC Marín, S Rodríguez, G Castellano, AJ Del Pozo
Journal: Endoscopy (2014)

Introducción: La CPRE es de elección en el tratamiento de litiasis biliares extrahepáticas. La esfinterotomía asociado a balón de Fogarty o cesta de Dormia alcanzan más del 80% de éxito al primer intento en litiasis sencillas. En coledocolitiasis > 15 mm los resultados publicados con técnica convencional son desalentadores (éxito: 12%). Papiloplastia y precorte pueden ser alternativas eficaces y seguras para estas litiasis.
P166 Role of Bronchoscopy in Patients with Haemoptysis and a Normal CT Scan: Abstract P166 Table 1
Authors: S Sharma, A Poorghobad, M Wood
Journal: Thorax (2012)

<h3>Aims and Objectives</h3> To investigate the merits of conducting bronchoscopies in patients with haemoptysis and normal or non-diagnostic CT scan. <h3>Methods</h3> Using the in-hospital bronchoscopy reporting tool, a retrospective analysis was carried out of the bronchoscopies performed on patients with haemoptysis but non-diagnostic CT scan. <h3>Results</h3> Between September 2008 and December 2011, a total of 450 bronchoscopies were performed. After excluding the patients with CT scan abnormalities which could explain the haemoptysis, medical notes of the remaining 99 patients were analysed. Out of these, 74 patients had a significant smoking history. 79 bronchoscopes were normal with the remaining 20 examinations revealing benign pathologies. These included generalised erythema, inflammation, purulent secretions and cartilagenous nodules. No new diagnosis of malignancy was made. <h3>Conclusions</h3> Results of our study suggest that a normal CT scan examination has a high negative predictive value for lung cancer. Further studies would be beneficial to ascertain the role of bronchoscopy in the investigative pathway of lung cancer in patients with normal CT scan.
Renal Tubular Acidosis in Carnitine Palmitoyltransferase Type 1 Deficiency
Authors: Zipora C. Falik-Borenstein, Stanley C. Jordan, Jean-Marie Saudubray, Michele Brivet, France Demaugre, John Edmond, Stephen D. Cederbaum
Journal: New England Journal of Medicine (1992)

THE importance of the normal metabolism of long-chain fatty acids has been emphasized by the increasing number of reports of the association of defects in this pathway with serious and even fatal i...
Respiratory Failure Associated with Familial Depression of Ventilatory Response to Hypoxia and Hypercapnia
Authors: Gerald C. Moore, Clifford W. Zwillich, Jane Donohue Battaglia, Ernest K. Cotton, John V. Weil
Journal: New England Journal of Medicine (1976)

Respiratory failure has been associated with depressed ventilatory responses to hypoxia or hypercapnia or both. The possibility that familial factors are responsible for decreased chemosensitivity prompted this study of a child with unexplained respiratory failure and normal lung function. We found his ventilatory response to hypoxia and hypercapnia to be virtually absent. Studies of six healthy immediate family members (parents and siblings) showed that hypoxic response, as measured by an index of the relation between ventilation and hypoxia (index A), was consistently reduced: 45 +/- 8.7 S.E.M. (normal, 127 +/- 8.7) (P less than 0.005). Response to hypercapnia, measured as the slope of the ventilatory response to hypercapnia, was lower than normal, averaging 0.95 +/- 0.16 liters per minute per millimeter of mercury (normal, 1.76 +/- 0.13) (P less than 0.01). The patient's respiratory failure seemed related to deficient ventilatory responses to hypoxia and hypercapnia. It seems likely that this depressed hypoxic response is of familial origin.